Literature DB >> 19498406

Prostate cancer: estimating the benefits of PSA screening.

Andrew J Vickers, Hans Lilja.   

Abstract

Two groundbreaking trials have this year reported conflicting results as to the benefit of screening for prostate cancer. Careful interpretation in the light of contemporary data is needed to reveal the value of this intervention.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19498406      PMCID： PMC2862723          DOI： 10.1038/nrurol.2009.95

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


  10 in total

1.  Cancer detection and cancer characteristics in the European Randomized Study of Screening for Prostate Cancer (ERSPC)--Section Rotterdam. A comparison of two rounds of screening.

Authors:  Renske Postma; Fritz H Schröder; Geert J L H van Leenders; Robert F Hoedemaeker; Andre N Vis; Monique J Roobol; Theodorus H van der Kwast
Journal:  Eur Urol       Date:  2007-01-16       Impact factor: 20.096

2.  Prostate cancer screening decreases the absolute risk of being diagnosed with advanced prostate cancer--results from a prospective, population-based randomized controlled trial.

Authors:  Gunnar Aus; Svante Bergdahl; Pär Lodding; Hans Lilja; Jonas Hugosson
Journal:  Eur Urol       Date:  2006-07-28       Impact factor: 20.096

3.  Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial.

Authors:  Anthony L Zietman; Michelle L DeSilvio; Jerry D Slater; Carl J Rossi; Daniel W Miller; Judith A Adams; William U Shipley
Journal:  JAMA       Date:  2005-09-14       Impact factor: 56.272

4.  Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years.

Authors:  Hans Lilja; David Ulmert; Thomas Björk; Charlotte Becker; Angel M Serio; Jan-Ake Nilsson; Per-Anders Abrahamsson; Andrew J Vickers; Göran Berglund
Journal:  J Clin Oncol       Date:  2007-02-01       Impact factor: 44.544

5.  Screening and prostate-cancer mortality in a randomized European study.

Authors:  Fritz H Schröder; Jonas Hugosson; Monique J Roobol; Teuvo L J Tammela; Stefano Ciatto; Vera Nelen; Maciej Kwiatkowski; Marcos Lujan; Hans Lilja; Marco Zappa; Louis J Denis; Franz Recker; Antonio Berenguer; Liisa Määttänen; Chris H Bangma; Gunnar Aus; Arnauld Villers; Xavier Rebillard; Theodorus van der Kwast; Bert G Blijenberg; Sue M Moss; Harry J de Koning; Anssi Auvinen
Journal:  N Engl J Med       Date:  2009-03-18       Impact factor: 91.245

6.  Mortality results from a randomized prostate-cancer screening trial.

Authors:  Gerald L Andriole; E David Crawford; Robert L Grubb; Saundra S Buys; David Chia; Timothy R Church; Mona N Fouad; Edward P Gelmann; Paul A Kvale; Douglas J Reding; Joel L Weissfeld; Lance A Yokochi; Barbara O'Brien; Jonathan D Clapp; Joshua M Rathmell; Thomas L Riley; Richard B Hayes; Barnett S Kramer; Grant Izmirlian; Anthony B Miller; Paul F Pinsky; Philip C Prorok; John K Gohagan; Christine D Berg
Journal:  N Engl J Med       Date:  2009-03-18       Impact factor: 91.245

7.  Effects of pathologic stage on the learning curve for radical prostatectomy: evidence that recurrence in organ-confined cancer is largely related to inadequate surgical technique.

Authors:  Andrew J Vickers; Fernando J Bianco; Mithat Gonen; Angel M Cronin; James A Eastham; Deborah Schrag; Eric A Klein; Alwyn M Reuther; Michael W Kattan; J Edson Pontes; Peter T Scardino
Journal:  Eur Urol       Date:  2008-01-14       Impact factor: 20.096

8.  The surgical learning curve for prostate cancer control after radical prostatectomy.

Authors:  Andrew J Vickers; Fernando J Bianco; Angel M Serio; James A Eastham; Deborah Schrag; Eric A Klein; Alwyn M Reuther; Michael W Kattan; J Edson Pontes; Peter T Scardino
Journal:  J Natl Cancer Inst       Date:  2007-07-24       Impact factor: 13.506

9.  The influence of finasteride on the development of prostate cancer.

Authors:  Ian M Thompson; Phyllis J Goodman; Catherine M Tangen; M Scott Lucia; Gary J Miller; Leslie G Ford; Michael M Lieber; R Duane Cespedes; James N Atkins; Scott M Lippman; Susie M Carlin; Anne Ryan; Connie M Szczepanek; John J Crowley; Charles A Coltman
Journal:  N Engl J Med       Date:  2003-06-24       Impact factor: 91.245

10.  Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: a case-control study.

Authors:  David Ulmert; Angel M Cronin; Thomas Björk; Matthew F O'Brien; Peter T Scardino; James A Eastham; Charlotte Becker; Göran Berglund; Andrew J Vickers; Hans Lilja
Journal:  BMC Med       Date:  2008-02-15       Impact factor: 8.775
  10 in total
  9 in total

1.  Screening for Prostate Cancer Starting at Age 50-54 Years. A Population-based Cohort Study.

Authors:  Sigrid Carlsson; Melissa Assel; David Ulmert; Axel Gerdtsson; Jonas Hugosson; Andrew Vickers; Hans Lilja
Journal:  Eur Urol       Date:  2016-04-13       Impact factor: 20.096

Review 2.  Screening for prostate cancer: early detection or overdetection?

Authors:  Andrew J Vickers; Monique J Roobol; Hans Lilja
Journal:  Annu Rev Med       Date:  2011-11-03       Impact factor: 13.739

3.  Common genetic variants in prostate cancer risk prediction--results from the NCI Breast and Prostate Cancer Cohort Consortium (BPC3).

Authors:  Sara Lindström; Fredrick R Schumacher; David Cox; Ruth C Travis; Demetrius Albanes; Naomi E Allen; Gerald Andriole; Sonja I Berndt; Heiner Boeing; H Bas Bueno-de-Mesquita; E David Crawford; W Ryan Diver; J Michael Gaziano; Graham G Giles; Edward Giovannucci; Carlos A Gonzalez; Brian Henderson; David J Hunter; Mattias Johansson; Laurence N Kolonel; Jing Ma; Loïc Le Marchand; Valeria Pala; Meir Stampfer; Daniel O Stram; Michael J Thun; Anne Tjonneland; Dimitrios Trichopoulos; Jarmo Virtamo; Stephanie J Weinstein; Walter C Willett; Meredith Yeager; Richard B Hayes; Gianluca Severi; Christopher A Haiman; Stephen J Chanock; Peter Kraft
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-01-11       Impact factor: 4.254

4.  Empirical estimates of the lead time distribution for prostate cancer based on two independent representative cohorts of men not subject to prostate-specific antigen screening.

Authors:  Caroline J Savage; Hans Lilja; Angel M Cronin; David Ulmert; Andrew J Vickers
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-04-20       Impact factor: 4.254

5.  Comparative effectiveness of alternative prostate-specific antigen--based prostate cancer screening strategies: model estimates of potential benefits and harms.

Authors:  Roman Gulati; John L Gore; Ruth Etzioni
Journal:  Ann Intern Med       Date:  2013-02-05       Impact factor: 25.391

6.  Estimating the harms and benefits of prostate cancer screening as used in common practice versus recommended good practice: A microsimulation screening analysis.

Authors:  Sigrid V Carlsson; Tiago M de Carvalho; Monique J Roobol; Jonas Hugosson; Anssi Auvinen; Maciej Kwiatkowski; Arnauld Villers; Marco Zappa; Vera Nelen; Alvaro Páez; James A Eastham; Hans Lilja; Harry J de Koning; Andrew J Vickers; Eveline A M Heijnsdijk
Journal:  Cancer       Date:  2016-07-26       Impact factor: 6.860

Review 7.  Alternative splicing and biological heterogeneity in prostate cancer.

Authors:  Prabhakar Rajan; David J Elliott; Craig N Robson; Hing Y Leung
Journal:  Nat Rev Urol       Date:  2009-08       Impact factor: 14.432

8.  Prostate-specific antigen velocity for early detection of prostate cancer: result from a large, representative, population-based cohort.

Authors:  Andrew J Vickers; Tineke Wolters; Caroline J Savage; Angel M Cronin; M Frank O'Brien; Kim Pettersson; Monique J Roobol; Gunnar Aus; Peter T Scardino; Jonas Hugosson; Fritz H Schröder; Hans Lilja
Journal:  Eur Urol       Date:  2009-08-07       Impact factor: 20.096

9.  Effect of alpha linolenic acid supplementation on serum prostate specific antigen (PSA): results from the alpha omega trial.

Authors:  Ingeborg A Brouwer; Johanna M Geleijnse; Veronique M Klaasen; Liesbeth A Smit; Erik J Giltay; Janette de Goede; Annemieke C Heijboer; Daan Kromhout; Martijn B Katan
Journal:  PLoS One       Date:  2013-12-11       Impact factor: 3.240
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.